^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

Two novel ALK mutations mediate acquired resistance to the next generation ALK inhibitor alectinib

Excerpt:
Both ALK mutations conferred resistance to alectinib as well as to crizotinib, but were sensitive to ceritinib and other next-generation ALK-TKIs. Treatment of the patient with ceritinib led to a marked response.
DOI:
10.1158/1078-0432.CCR-14-1511